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Background 
In post-operative patients, limited mobility can lead to increased morbid-
ity and mortality due to venous thromboembolism (VTE), which is a 
life-threatening complication consisting of either deep vein thrombosis 
(DVT) or pulmonary embolism (PE). Prophylaxis with anticoagulants is 
often recommended for this patient group for this reason.1·3 In general 
surgery patients without prophylaxis, DVT incidence is approximately 25 
percent.3 Patients undergoing more mobility-limiting procedures, such as 
total hip or knee replacement surgery or hip fracture surgery, DVT rates 
are at rates of up to 35-60 percent. With regard to PE, prevalence varies 
greatly depending on the site of surgery but overall is an important con-
sideration due to the high potential for patient harm. Without prophylaxis, 
general surgery patients have a PE incidence of 1.6 percent, with 0.9 
percent fatality. With an increase in procedure complexity, PE incidence 
can go as high as 3.6-12.9 percent, such as in hip fracture surgery.14 
The effectiveness of anticoagulation prophylaxis often is weighed 
against the safety risks and administration issues of available treat-
ments, and these issues can leave physicians looking for better options. 
As addressed in the previous issue of The Pharmacy and Wellness 
Review, development of new anticoagulation agents for prophylaxis of 
VTE has been underway as drug companies aim to create orally avail-
able agents that target the clotting cascade in specific ways to avoid 
undesired coagulation while minimizing patient bleeding risk.5 The goal 
of these new therapeutic agents is to ease patient administration and 
increase tolerability while being as effective or better than currently 
available agents in prevention of VTE. Specific targets for therapy 
include Factors Ila and Xa. Select anticoagulants showing promise in 
the pipeline include dabigatran, a direct thrombin (Factor Ila) inhibitor, 
which was discussed in a previous issue of The Pharmacy and Well-
ness Review (May 2010), and rivaroxaban, a direct Factor Xa inhibitor. 
Dabigatran was recently given approval by the Food and Drug Admin-
istration (FDA). Rivaroxaban has been granted approval for use in both 
the European Union and Canada since September 2008.6 Rivaroxaban 
was submitted in July 2008 for U.S. FDA approval. It was approved by 
the FDA advisory committee but was denied by the FDA with a need for 
more information, which the manufacturer, Bayer, is preparing.3•5•6 
Rivaroxaban is a competitive, selective and reversible Factor Xa inhibi-
tor. The bioavailability is greater than 80 percent and is not affected 
by food, leading to a half-life of approximately nine hours, which may 
be prolonged in the elderly.7 Renal excretion accounts for two-thirds of 
elimination, while the rest is eliminated in the feces via P-glycoprotein 
and some hepatic metabolism by the CYP450 enzyme system. It is 
possible that inhibition of CYP3A4 could cause an increase in plasma 
levels. Rivaroxaban has a contraindication in renal failure (CrCI <30 ml/ 
min) due to lack of evidence. Early dose-finding studies in hip or knee 
replacement found rivaroxaban did not have a true dose-response 
relationship with regards to efficacy, but bleeding risk did increase 
proportionally with increases in dosage. The optimal dose was found to 
be between 5 and 20 mg, and rivaroxaban is available as a 1 O mg tablet 
in countries where it is approved. 
Efficacy 
Several trials concluded efficacy exists for regular clinical use of rivar-
oxaban in patients. The RECORD 1 and 4 trials had a primary efficacy 
composite endpoint of any DVT (proximal or distal), confirmed non-fatal 
PE, and all cause mortality during treatment.8•9 The RECORD 4 trial 
had 366 patients eligible for the efficacy analysis with symptomatic DVT 
during follow-up confirmed by venography or ultra-sound.9 Using the 
composite data, 44.3 percent of patients on enoxaparin 40 mg daily 
had some complication included in the composite endpoint. The 10 mg 
twice-daily dose of rivaroxaban did considerably better, with only 23.3 
percent of patients having a complication (p=0.29). The 5 mg twice-daily 
rivaroxaban dose had similar efficacy to enoxaparin, with 40.4 percent 
having complications. Major VTE occurred in patients ranging from rates 
of 0-6.7 percent with various doses of rivaroxaban versus 4.3 percent 
with enoxaparin. All rivaroxaban dose-range groups investigated had 
efficacy similar to twice-daily enoxaparin beginning the day after surgery. 
Alternatively, RECORD 1 compared 10 mg rivaroxaban to 40 mg enox-
aparin in patients receiving VTE prophylaxis after hip arthroplasty and 
found rivaroxaban to be more efficacious than enoxaparin.8 At the end 
of the trial, 69 percent of 4,541 patients were included in the superiority 
analysis, with venography required for inclusion. The primary composite 
endpoint of complications occurred in 1. 1 percent in the rivaroxaban 
group and 3.7 percent in the enoxaparin group (p < 0.001 ), with major 
VTE occurring in 0.2 percent of the rivaroxaban group contrasted with 
2 percent of enoxaparin patients. Major bleeding was observed in 0.3 
percent of the rivaroxaban group versus 0.1 percent with enoxaparin. 
Another study, RECORD 2, looked at an extended duration of rivaroxa-
ban versus short-term enoxaparin use for prevention of VTE after hip 
arthroplasty.10 This study used a modified intention-to-treat analysis for 
the primary efficacy of 864 patients in the rivaroxaban group and 869 
patients in the enoxaparin group. The primary endpoint occurred in 2 
percent of the rivaroxaban group and 9.3 percent in the enoxaparin 
group. The incidence of bleeding was similar in both groups (6.6 percent 
for rivaroxaban versus 5.5 percent with enoxaparin). Extended thrombo-
prophylaxis was concluded to be more effective with rivaroxaban than 
short-term enoxaparin. 
A trial independent of the RECORD series, known as the Einstein Study, 
was a randomized, dose-ranging, double-blind, open-labeled study that 
compared rivaroxaban to low molecular weight heparin (LMWH) and 
vitamin K antagonist (VKA) therapy per hospital protocol until an INR of 
2-3 was reached in patients with acute symptomatic DVTs.11 Of the 543 
patients in the study, 449 were eligible to be included in the per-protocol 
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analysis. With a primary efficacy composite outcome of symptomatic 
recurrent DVT, symptomatic fatal/nonfatal PE and asymptomatic deterio-
ration in negative thrombotic effects, rivaroxaban was found to be more 
efficacious than LMWHNKA. The LMWHNKA group had 9 percent of 
patients experience the primary efficacy endpoint compared to 5.4-6.6 
percent of rivaroxaban patients. With the 5-20 mg rivaroxaban range 
deemed to be efficacious, the 20 mg dose was found to be most effec-
tive in preventing DVT recurrences. 
Safety 
The phase II ATLAS trial was a double-blind, open-label, with block 
randomization of 1 :1 :1 placebo:rivaroxaban (doses 5-20 mg) once 
daily:rivaroxaban (2.5-1 O mg) twice daily with at least 225 patients per 
tier.6 The study called for liver function tests to take place once a month 
during the study. The safety endpoint consisted of clinically signifi-
cant bleeding requiring assistance, such as lab tests or surgery. Liver 
function tests revealed no significant difference in the rate of alanine 
aminotransferase greater than three times the upper limit of normal in 
patients given rivaroxaban compared with placebo (3. 7 percent versus 
4.5 percent, respectively). Clinically significant bleeding occurred in a 
dose-dependent manner compared to placebo.12 
Rivaroxaban was compared to enoxaparin in a randomized, double-
blind/dummy study, active-comparator-controlled, multi-national study in 
873 patients undergoing hip replacement surgery that received prophy-
laxis of VTE between six and eight hours post-operation.13 The primary 
safety outcome was the incidence of major bleeding, which ranged from 
O. 7 percent wtth the 10 mg rivaroxaban dose to 5.1 percent with the 40 
mg dose. The study determined no significant difference in incidence 
of major post-operation bleeding between rivaroxaban and enoxaparin. 
A total of 845 patients was used in the safety population data, which 
determined a significant dose-response relationship (p=0.0391).13 
In RECORD 1 when dosing rivaroxaban, the occurrence of major VTE 
decreased while the risk of major bleeding increased compared to 
enoxaparin, suggesting the patient's status should be considered when 
selecting therapy.10 A challenge in the approval process for rivaroxaban 
is the lack of power for safety outcomes in the studies. Post-marketing 
pharmacovigilance should provide more data on the safety of rivaroxa-
ban. 
Place In therapy 
Based on safety and efficacy data, rivaroxaban has evidence that it 
could be an effective treatment in VTE prophylaxis in post-surgical 
patients. Further studies, including post-marketing surveillance, could 
help to reinforce this evidence. There are no currently published studies 
looking into efficacy and safety of rivaroxaban in comparison to warfarin 
in VTE. The ROCKET-AF trial looking at rivaroxaban in atrial fibrilla-
tion versus warfarin is currently ongoing, and results will help to further 
determine rivaroxaban's usefulness long-term.11 
Although rivaroxaban has been shown to be clinically useful in patients, 
some concern was raised over the degree of benefit over enoxaparin 
in the RECORD trial series results due to inherent trial/design issues. 
Specifically, Van Thiel raised awareness in an editorial that enoxaparin 
dosing was inconsistent with recommendations in the United States and 
that less-than-optimum duration and dosing prevented maximum enoxa-
parin benefit in comparison to rivaroxaban.15 Lack of power for differ-
ences in major bleeding, as well as some questionable safety evaluations 
compared to current recommendations, also weakened the findings of 
this extensive study. While these points are justified, the trial program did 
demonstrate promising results for rivaroxaban as an atternative agent for 
VTE prophylaxis. With varying international standards for prophylaxis and 
new CHEST guidelines, which were published after the trials had been 
conducted, the issues do not seem to limit rivaroxaban therapy for con-
sideration. Slated to finish in fall 2010, the ROCKET-AF trial will provide 
results detailing the clinical comparison of rivaroxaban to warfarin. 11 The 
FDA Advisory Panel has requested more data of Bayer, rivaroxaban's 
manufacturer, which is not likely to be submitted until late 201 O or early 
2011, meaning FDA approval will be delayed until 2011 at the earliest.16 
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